How Much Does Prolia (Denosumab) Cost in Arkansas in 2026?

Arkansas Retail Pricing for Prolia in 2026

The average cash-pay price for a single 60 mg Prolia injection at Arkansas retail pharmacies sits near $1 to 500 in 2026. This reflects Amgen's wholesale acquisition cost, which has remained relatively stable since the drug's 2010 approval. Because Prolia is a physician-administered biologic (subcutaneous injection given every six months), many patients receive it in a clinic setting rather than filling a traditional pharmacy prescription.

Hospital outpatient departments and specialty infusion centers in Little Rock, Fayetteville, and Jonesboro bill under Medicare Part B code J0897 for denosumab administration. The total facility charge (drug + administration fee) can exceed $1,800 per visit before insurance adjustments. Patients receiving Prolia at a physician's office typically face lower facility fees.

For the two-injection annual course, unassisted out-of-pocket spending reaches approximately $3,000. This positions Prolia as one of the more expensive osteoporosis therapies compared to generic oral bisphosphonates like alendronate (approximately $15 to $30 per month) 1. The cost differential is significant, but so is the clinical benefit profile for patients who cannot tolerate oral bisphosphonates or who have severe fracture risk.

Arkansas Medicaid Coverage and Prior Authorization

Arkansas Medicaid does cover Prolia (denosumab) for eligible beneficiaries, though the program requires prior authorization (PA). The PA process generally demands documentation of one or more of the following: a T-score of −2.5 or lower on dual-energy X-ray absorptiometry (DXA), a history of fragility fracture, or documented intolerance or contraindication to oral bisphosphonates.

The Arkansas Department of Human Services Pharmacy Program processes PA requests through its preferred drug list (PDL) system. Prescribers submit clinical documentation showing the patient meets medical necessity criteria established under Endocrine Society guidelines for osteoporosis management. Approval timelines vary, but most decisions arrive within 72 hours for standard requests and 24 hours for urgent requests.

Arkansas expanded Medicaid under the ARHOME program covers adults aged 19 to 64 with incomes up to 138% of the federal poverty level. These beneficiaries follow the same PA pathway. Dual-eligible patients (Medicare + Medicaid) receive Prolia under Medicare Part B with Medicaid covering remaining cost-sharing obligations.

Insurance Coverage Across Arkansas Plans

Most major commercial insurance carriers operating in Arkansas cover Prolia under their medical benefit (not pharmacy benefit) when billed as a physician-administered injection. Blue Cross Blue Shield of Arkansas, Ambetter (administered by Celtic Insurance Company), QualChoice, and UnitedHealthcare Community Plan all include denosumab on their formularies with varying cost-sharing structures 2.

Typical commercial plan structures for Prolia in Arkansas:

PPO plans generally apply the specialist visit copay ($40 to $75) plus a percentage coinsurance on the drug itself (often 20% after deductible). A patient with a $2,000 deductible who has not yet met it would pay the full $1,500 for their first injection of the calendar year.

HMO plans may require step therapy documentation showing failure of or intolerance to a first-line bisphosphonate before approving Prolia. Once approved, copays range from $50 to $150 per injection depending on the plan tier.

Medicare Advantage plans in Arkansas (Humana, Aetna, UAMS Health Advantage) cover Prolia under Part B with the standard 20% coinsurance after the Part B deductible ($257 in 2026). A Medigap supplemental policy eliminates this coinsurance for most beneficiaries.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared to placebo 1. These outcomes data form the clinical basis insurers use when evaluating coverage for the drug.

The Amgen Savings Card in Arkansas

Amgen offers the Prolia Complete savings card program for commercially insured patients. In Arkansas, eligible patients can reduce their out-of-pocket cost to $0 per injection, with Amgen covering up to $1 to 750 in copay or coinsurance per injection. The program covers up to four injections over two years.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Prolia, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, Tricare, VA), and must be a resident of the United States. Arkansas patients meeting these criteria can enroll at the prescriber's office or through Amgen's patient support line.

"For patients with commercial insurance, out-of-pocket costs should never be a barrier to receiving prescribed osteoporosis therapy," noted the American Association of Clinical Endocrinology (AACE) 2020 guidelines on osteoporosis treatment access. The Amgen savings card effectively addresses this for the commercially insured population, though it leaves Medicare beneficiaries without manufacturer copay assistance due to federal anti-kickback statute restrictions.

Compounded Denosumab Through 503A Pharmacies in Arkansas

Compounded denosumab is available in Arkansas through licensed 503A compounding pharmacies. Under the Drug Quality and Security Act (DQSA), section 503A pharmacies may compound drugs based on valid patient-specific prescriptions when a prescriber determines a clinical need 3. Arkansas Board of Pharmacy regulations permit these operations provided the pharmacy holds a valid state license and complies with USP 797 sterile compounding standards.

Several factors drive patients toward compounded alternatives. Cost is the primary motivator. Compounded biologic preparations may carry significantly lower price points than branded Prolia, though pricing varies by pharmacy and preparation complexity. Patients should confirm that any compounded denosumab product meets appropriate potency, sterility, and stability standards.

The legal framework in Arkansas permits 503A compounding of denosumab when prescribed for an individual patient by a licensed prescriber. Arkansas does not impose additional state-level restrictions beyond federal 503A requirements. Patients considering this route should verify that their chosen pharmacy holds current Arkansas Board of Pharmacy compounding licensure and maintains appropriate cold-chain storage for biologic preparations.

It is worth noting that compounded biologics are not FDA-approved products and do not carry the same regulatory oversight as Amgen's branded Prolia. The FDA has stated that compounded drugs are not evaluated for safety, efficacy, or manufacturing quality in the same manner as approved drugs.

Telehealth Prescribing of Prolia in Arkansas

Arkansas permits telehealth prescribing of Prolia (denosumab). The Arkansas Telemedicine Act allows licensed physicians to establish patient-provider relationships via audiovisual telecommunication and prescribe medications, including injectable biologics, based on that virtual encounter. This means an Arkansas patient can receive a denosumab prescription from a board-certified endocrinologist or rheumatologist without an in-person visit for the initial evaluation.

The prescribing event and the administration event are separate, however. While a telehealth clinician can write the prescription and submit prior authorization paperwork, the actual subcutaneous injection still requires either a clinic visit or home health nursing visit. Some Arkansas home health agencies and mobile injection services now offer in-home Prolia administration, reducing travel burden for rural patients in the Delta region or western Ozark communities.

The Endocrine Society's position on telehealth supports virtual management of osteoporosis, including ordering DXA scans, reviewing results, and prescribing antiresorptive therapy remotely. Arkansas has no additional telehealth prescribing restrictions specific to biologics beyond standard controlled substance limitations (which do not apply to denosumab, as it is not a controlled substance).

Patient Assistance for Uninsured Arkansas Residents

Amgen operates the FIRST STEP program for uninsured patients who meet income eligibility criteria (generally household income at or below 300% of the federal poverty level). Qualifying Arkansas residents receive Prolia at no cost. The application requires documentation of income, a completed prescription form from the treating physician, and a statement that the patient lacks prescription drug coverage.

Additional resources available to Arkansas residents:

The NeedyMeds database lists supplemental assistance programs and discount options. The Osteoporosis Foundation also maintains a patient assistance directory. Arkansas patients near the Missouri or Tennessee borders may find pricing variations at pharmacies in neighboring states, though this strategy requires careful coordination with prescribers regarding billing and administration logistics.

For Medicare beneficiaries facing the 20% Part B coinsurance (approximately $300 per injection), Medicare Supplement (Medigap) plans C, D, F, and G cover this coinsurance in full. Arkansas Medicare beneficiaries enrolled in these supplement plans effectively pay $0 out-of-pocket for Prolia beyond their monthly Medigap premium.

Clinical Context: Why Cost Matters for Adherence

Discontinuation of denosumab carries specific clinical risks that make cost-related nonadherence particularly dangerous. The FREEDOM Extension study demonstrated that patients who discontinued denosumab experienced rapid bone mineral density loss, returning to pre-treatment levels within 12 to 18 months, along with an increased risk of multiple vertebral fractures 4. This rebound phenomenon does not occur with bisphosphonate discontinuation.

"Patients must be counseled that stopping denosumab without transitioning to an alternative antiresorptive agent poses a real risk of rebound vertebral fractures," according to the 2020 AACE/ACE guidelines. This guideline specifically recommends that cost barriers be addressed proactively to prevent unplanned treatment gaps.

In Arkansas, where median household income ($56 to 335 in 2024 Census estimates) falls below the national median, cost sensitivity is a real driver of adherence failure. The 6-month dosing interval helps. Patients face only two cost events per year rather than monthly refill decisions. But a single $1,500 bill arriving unexpectedly (for instance, if a savings card expires or insurance changes mid-year) can derail treatment continuity.

Comparing Prolia Cost to Alternatives in Arkansas

For context, here is how Prolia pricing in Arkansas compares to other osteoporosis therapies available in the state:

Generic alendronate (Fosamax): $4 to $30 per month at most Arkansas pharmacies. Covered by all plans without prior authorization. However, oral bisphosphonates require fasting administration, carry GI side effect risk, and are contraindicated in patients with esophageal disorders or inability to remain upright for 30 minutes 5.

Zoledronic acid (Reclast): $1,100 to $1,400 per annual IV infusion. Covered under medical benefit with PA. Offers once-yearly dosing, but requires IV access and carries risk of acute-phase reactions (fever, myalgia) in approximately 30% of first-time recipients.

Teriparatide (Forteo): $3,800 per month for daily subcutaneous injection. Reserved for severe osteoporosis, limited to 24 months of use. Substantially more expensive than Prolia but serves a different clinical role as an anabolic agent.

Romosozumab (Evenity): approximately $1,825 per monthly injection for 12 months. Newer agent with both anabolic and antiresorptive properties. Carries a cardiovascular risk warning and is contraindicated in patients with recent MI or stroke 6.

Prolia occupies a middle tier in both efficacy and cost. Its every-6-month subcutaneous injection offers convenience over daily or weekly oral medications, while its price point sits well below anabolic agents like teriparatide and romosozumab.

Steps to Minimize Your Prolia Cost in Arkansas

Patients and prescribers in Arkansas should follow a specific sequence to minimize out-of-pocket exposure. First, verify insurance coverage and benefit type (medical vs. pharmacy). Second, submit prior authorization with supporting DXA results and clinical documentation. Third, apply for the Amgen savings card if commercially insured. Fourth, if uninsured or underinsured, apply for Amgen FIRST STEP. Fifth, if Medicare-enrolled, confirm Medigap or Medicare Advantage coinsurance coverage. Sixth, if all other options are exhausted, discuss compounded denosumab through a licensed 503A pharmacy with the treating physician.

Arkansas patients receiving Prolia should set calendar reminders for their 6-month injection window. Missing the scheduled dose by more than 4 weeks increases rebound fracture risk and may require re-authorization with insurance.